Evidence map›Paper›PMID 33145312›Full record

ReviewAnnals of translational medicine2020

Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review.

Weijing Li, Lili Wu, Chen Huang, Ruixia Liu, Zheng Li, Lihong Liu, Baoen Shan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weijing LiDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lili WuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chen HuangDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ruixia LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zheng LiDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lihong LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Baoen ShanCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy has achieved good therapeutic efficacy in the treatment of hematological malignancies. In August 2017, Novartis Kymriah (CAR-T cells targeting CD19) was approved by the FDA, indicating the real entry of CAR-T cell therapy into clinical applications and making CAR-T cell therapy the most attractive technology in the field of tumor treatment. In October 2017, the FDA approved the world's second CAR-T cell therapy-Yescarta. The launch of these products has attracted wide attention to CAR-T cell therapy. CAR-T cell therapy has achieved significant effect in the treatment of tumors, however, CAR-T therapy also faces clinical problems, such as cytokine release syndrome (CRS), poor therapeutic efficacy in solid tumors, and high rates of tumor recurrence. At present, the side effects of CAR-T therapy have attracted a large amount of attention, which has resulted in investigations into strategy establishment. With a deepening understanding of CAR-T therapy and the continuous optimization of therapeutic regimens, its toxicity and side effects have been partially controlled. This study set out to analyze the problems in the clinical application of CAR-T therapy encountered in recent years and to introduce corresponding strategies, with the aim of providing a basis of reference for clinicians and scientists in the management of CAR-T therapy in clinical practice and in the CAR-T therapy research.

Indexed as

Chimeric antigen receptor T-cell (CAR-T)cytokine release syndrome (CRS)solid tumor treatmentstrategytumor recurrence

Identifiers

PMID33145312
PMCPMC7575947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.